Home  »  News   »  Nordic American Tankers Limited (NAT) Vs. ZIOPHARM...

Nordic American Tankers Limited (NAT) Vs. ZIOPHARM Oncology Inc. (ZIOP): Which Is Riskier?

Nordic American Tankers Limited (NYSE: NAT) shares are -14.43% down in the year-to-date (YTD) period and have moved -3.44% or -$0.15 lower in the latest trading session. However, stock’s trailing 12-month performance remains nearly +83.04% lower. Comparatively, the stock is -53.22% down YTD and -4.75% over the trailing 3-month period. If we look at the shorter duration, its week performance is -6.65% and -6.03% over the month.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Analyst Recommendations

On October 18, 2019, Evercore ISI recommended the NAT stock is a In-line, while earlier, Evercore ISI had Downgrade the stock as a Underperform on May 04, 2020. 7 analysts offering the recommendations for the stock have a consensus rating of 2.30 to suggest that the NAT stock is a “Moderate Buy. 2 of the 7 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 4 recommend buying, with 0 rating it as an Overweight.

The stock currently trades at $4.21 and analysts tracking its performance over the next 12 months have a consensus estimate price target of $6.28. The forecasts give the Nordic American Tankers Limited stock a price target range of $8.00 on the higher side while at least one analyst think the stock could plunge to a low of $1.40. The two limits represent an upside potential of 47.38% or -200.71%.

Earnings Forecast

Analysts estimate the earnings to increase 17.90% in the current quarter to -$0.04, up from the -$0.1 reported in the same quarter a year ago. For the current year, earnings should grow to an average of $0.6, up 53.20% from -$0.07 reported last year. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between -$0.05 and $0.19. Wall Street estimates earnings per share to be at an average of $0.47 for the next year.

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), on the other hand, is trading around $2.63 with a market cap of $550.85M and analyst research firms have a negative stance on its shares. Some analysts are even forecasting -$0.37 per share in earnings this year on a short term (1 year) basis.

Let us briefly look at the ZIOPHARM Oncology Inc. (ZIOP) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.

Company balance sheet and cash flow

ZIOP’s operating expenses over the recent quarter were at -$18.6 million. This represented a 199.95% of the company’s total revenues which amounted $18.61 million. With this in place, we can see that the company’s diluted EPS declined -$0.09 on the year-over-year period, shrinking to -$0.09 as given in the last earnings report.

In terms of the balance sheet & cash flow as of (Sep 2020), the total assets figure advanced to $181.68 million from $198.28 million over the previous quarter. The cash flow from operating activities totaled -$23.91 million, significantly lower than the -$18.32 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$27.91 million.

Insider activity

Insiders have transacted a total of 0 times at ZIOPHARM Oncology Inc. over the last 6 months, with insider purchases undertaken 0 times and accounting for 0 shares. Insider sales totaled 0 shares over the same period, with these deals completed in 0 transactions. Looking at these numbers, we realize that net purchases over that period are 0.0 shares. Insiders now hold a total of 15.14M shares after the latest sales, with 0.00% net shares purchased.

Major holders

Insiders own 7.12% of the company shares, while shares held by institutions stand at 54.90% with a share float percentage of 200.16M. Investors are also buoyed by the number of investors in a company, with ZIOPHARM Oncology Inc. having a total of 199 institutions that hold shares in the company.

Related Posts




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam